C19orf55 Inhibitors
C19orf55 inhibitors encompass compounds that interfere with different kinases and signaling pathways potentially related to the regulation and activity of C19orf55. For instance, kinase inhibitors like staurosporine, LY294002, and wortmannin target enzymes which, when inhibited, can lead to decreased phosphorylation of proteins that may interact with or regulate C19orf55, thus reducing its activity. The PI3K/AKT pathway, a common target of LY294002 and wortmannin, is a pivotal signaling cascade in cell survival and metabolism, and its inhibition can impact various proteins, potentially including C19orf55. If C19orf55's function is contingent upon PI3K/AKT-mediated signaling, the disruption of this pathway would likely compromise its activity.
Furthermore, inhibitors like rapamycin, U0126, PD98059, and sorafenib target the mTOR, MEK/ERK, and Raf pathways respectively. These pathways are integral to processes such as cell growth, proliferation, and differentiation. If C19orf55 plays a role in these processes or acts downstream of these pathways, the use of these inhibitors would result in a reduction of its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. Inhibition of protein kinases by staurosporine can lead to reduced phosphorylation of downstream proteins that are necessary for C19orf55 to exert its function, effectively diminishing C19orf55's activity in the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By preventing PI3K activity, LY294002 reduces the production of PIP3, which is crucial for AKT activation. Since AKT can regulate numerous proteins including those that may interact with C19orf55, the inhibition of this pathway can lead to a decrease in C19orf55 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that blocks the PI3K/AKT pathway. By inhibiting PI3K, wortmannin leads to a decrease in AKT-mediated signaling events, which could indirectly inhibit C19orf55 activity if C19orf55 is part of or regulated by this signaling pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits the mTOR complex 1 (mTORC1). Since mTORC1 is involved in protein synthesis and cell growth, its inhibition by rapamycin can result in the decreased activity of proteins related to these processes, including C19orf55 if it is involved in mTORC1 signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK1/2 inhibitor that interrupts the MAPK/ERK pathway. This pathway is key in regulating cell growth and differentiation. If C19orf55 is regulated by MEK1/2 or acts downstream of this pathway, U0126 would impede its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By blocking MEK, PD98059 can inhibit ERK activation, which in turn could reduce the activity of C19orf55 if it is regulated by the MAPK/ERK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, a kinase involved in inflammatory responses and stress signaling. Inhibition of p38 MAPK by SB203580 could lead to the inhibition of C19orf55 function if it plays a role in p38 MAPK-mediated signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which can block JNK-mediated signaling pathways involved in apoptosis and cellular stress responses. If C19orf55 is associated with JNK signaling, its functional activity would be inhibited by SP600125. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that can inhibit Src family kinases. By blocking these kinases, dasatinib can impede signaling pathways that may be essential for the activity of C19orf55. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of proteins. If C19orf55 requires proteasome-mediated degradation of regulatory proteins for its activity, bortezomib would increase the levels of these proteins, indirectly inhibiting C19orf55 function. | ||||||